
The stock price of Sana Biotechnology surged 160% on January 8, with intraday gains exceeding 300%. The company announced a groundbreaking achievement: successfully transplanting insulin-producing pancreatic cells into a patient with type 1 diabetes without the need for immunosuppression. Sana hopes this breakthrough will revolutionize the nearly $100 billion diabetes…